BAX and neoplasm: In contrast to DT-061 treatment, the combination of IBR and VEN inhibited tumor growth only in WT mice (~32.6%), but not the Bax/Bak-DKO group (~–4.3%) (Figure 6, A and B), further suggesting that the in vivo activity of this drug combination was dependent on the Bax/Bak pathway.